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Abstract
Background: HIV viral load (VL) is currently not part of the criteria for Pneumocystis jirovecii pneumonia (PCP) prophylaxis
discontinuation, but suppression of plasma viremia with antiretroviral therapy may allow for discontinuation of PCP
prophylaxis even with CD4 count ,200 cells/mL.
Methods: A systematic review was performed to determine the incidence of PCP in HIV-infected individuals with CD4 count
,200 cells/mL and fully suppressed VL on antiretroviral therapy but not receiving PCP prophylaxis.
Results: Four articles examined individuals who discontinued PCP prophylaxis with CD4 count ,200 cells/mL in the context
of fully suppressed VL on antiretroviral therapy. The overall incidence of PCP was 0.48 cases per 100 person-years (PY) (95%
confidence interval (CI) (0.06–0.89). This was lower than the incidence of PCP in untreated HIV infection (5.30 cases/100 PY,
95% CI 4.1–6.8) and lower than the incidence in persons with CD4 count ,200 cells/mL, before the availability of highly
active antiretroviral therapy (HAART), who continued prophylaxis (4.85/100 PY, 95% CI 0.92–8.78). In one study in which
individuals were stratified according to CD4 count ,200 cells/mL, there was a greater risk of PCP with CD4 count #100 cells/
mL compared to 101–200 cells/mL.
Conclusion: Primary PCP prophylaxis may be safely discontinued in HIV-infected individuals with CD4 count between 101–
200 cells/mL provided the VL is fully suppressed on antiretroviral therapy. However, there are inadequate data available to
make this recommendation when the CD4 count is #100 cells/mL. A revision of guidelines on primary PCP prophylaxis to
include consideration of the VL is merited.
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Introduction
Currently, The National Institutes of Health, the Centers for
Disease Control and Prevention and the HIV (Human Immuno-
deficiency Virus) Medicine Association of the Infectious Diseases
Society of America guidelines state that prophylaxis against
Pneumocystis jirovecii pneumonia (PCP) may be discontinued safely
in HIV-infected individuals when CD4 counts are maintained
.200 cells/mL for over three months on antiretroviral therapy [1].
This recommendation was made when prospective observational
and randomized controlled trials in the highly active antiretroviral
therapy (HAART) era demonstrated that discontinuation of PCP
prophylaxis was safe when a sustained CD4 count .200 cells/mL
was achieved [2–4].
Medications used for PCP prophylaxis include trimethoprim/
sulfamethoxazole (TMP-SMX), pentamidine, dapsone and atova-
quone. Adverse effects include anemia, hyperkalemia, renal
dysfunction, hypersensitivity reactions, rashes and hepatitis and
may occasionally be life-threatening [5,6]. TMP-SMX, the first-
line agent for PCP prophylaxis, may be associated with
hypersensitivity reactions such as Stevens-Johnson Syndrome
[5,6] and have been reported in up to 4% of the HIV population
[6]. Other disadvantages of prophylactic medications include
additional pill burden, drug interactions, and cost. For individuals
on inhaled pentamidine, there is also the inconvenience of
monthly clinic visits [7].
HIV viral load (VL) and changes in VL have clearly been shown
to be associated with the risk of development of OIs, independent
of CD4 count [7,8–11]. Mellors et al. examined longitudinal data
of 1,640 HIV patients registered in the Multicenter AIDS Cohort
Study (MACS). They demonstrated that median HIV-1 RNA
explained 51% and 58% of the variability in AIDS and death, and
median CD4 count accounted for 29% and 35% of this variability,
respectively. The authors concluded that, in patients with
untreated HIV infection, a single HIV-1 RNA measurement was
the strongest predictor of time to AIDS and death, explaining
about half of the variability in these clinical outcomes [10].
However, at present the HIV-RNA level, or VL, is not part of the
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prophylaxis, which are based almost entirely on CD4 counts [7].
Our goal was to perform a systematic review of the published
studies to determine the incidence of PCP in HIV-infected
individuals with fully-suppressed plasma VL on antiretroviral
therapy who discontinued PCP prophylaxis with CD4 count ,200
cells/mL. We then aimed to compare this incidence to 1) the
natural history rate of PCP in the HIV-infected population, 2) the
incidence of PCP in individuals who discontinued prophylaxis with
CD4l count .200 cells/mL and 3) the incidence of PCP in
individuals who continue prophylaxis with CD4 count ,200 cells/
mL prior to the availability of HAART. If it could be demonstrated
from this evidence that individuals whose CD4 count is ,200
cells/mL and VL are suppressed on antiretroviral therapy could
discontinue prophylaxis with a risk of acquiring PCP similar to
individuals in the other three groups, this finding would have
important clinical implications and would indicate that a revision
of clinical guidelines may be merited.
Methods
Literature Search
We conducted a systematic search of the literature to retrieve
articles examining the incidence of PCP in HIV-infected
individuals with fully-suppressed plasma VL on antiretroviral
therapy who discontinued PCP prophylaxis with CD4 count ,200
cells/mL, We searched OVID Medline (1950-August 8 2010),
EMBASE (1947 to 2010 week 31), the Cochrane Central Registry
of Controlled Trials (2005 to September 2010) and the Cochrane
Database of Systematic Reviews (3
rd quarter 2010) for original
studies and systematic reviews. Search terms used included
‘‘pneumonia,’’ ‘‘pneumocystis,’’ ‘‘pneumocystosis or carinii,’’
‘‘antibiotic prophylaxis or chemoprevention or preventative or
prevention,’’ ‘‘HIV infection or human immunodeficiency virus or
AIDS or acquired immune deficiency syndrome,’’ and ‘‘discon-
tinue or cease or stop or cessation or halt or terminate or
suspend.’’ Titles and abstracts were reviewed independently by
two investigators. When there was uncertainty regarding the
suitability of a study, full text articles were retrieved and the
articles were discussed between the two investigators until
agreement was reached. Bibliographies of several studies were
also reviewed to ensure all relevant studies were captured.
Studies examining 1) the natural history rate of PCP in the
HIV-infected population, 2) the incidence of PCP in individuals
who discontinued prophylaxis with CD4 count .200 cells/mL and
3) the incidence of PCP in individuals who continue prophylaxis
with CD4 count ,200 cells/mL prior to the availability of
HAART were retrieved by examining the reference list of the
Guidelines for prevention and treatment of opportunistic infec-
tions in HIV-infected adults and adolescents: recommendations
from CDC, the National Institutes of Health, and the HIV
Medicine Association of the Infectious Diseases Society of America
[1].
Eligibility
Studies in the English language were eligible. Abstracts were not
included.
Study Selection and Data Extraction
To address our primary study question, studies were selected if
they examined the incidence of PCP in adults who met the
following inclusion criteria: 1) HIV-infected, 2) CD4 count ,200
cells/mL, 3) fully suppressed VL as measured by conventional
assays 4) on antiretroviral therapy, and 5) discontinuation of PCP
prophylaxis (primary or secondary) or not already taking
prophylaxis. Studies in the other three categories were selected if
they were referenced in the current guidelines for prevention and
treatment of opportunistic infections in HIV-infected adults and
adolescents [1], recognizing that other studies in these categories
have been published. Data were extracted by two reviewers.
Analysis
Incidence rates of PCP in persons who discontinued prophylaxis
with CD4 count ,200 cells/mL and fully suppressed VL on
antiretroviral therapy were compared to 1) the natural history rate
of PCP in the HIV-infected population, 2) the incidence of PCP in
individuals who discontinued prophylaxis with CD4 count .200
cells/mL on antiretroviral therapy and 3) the incidence of PCP in
individuals who continued prophylaxis with CD4 count ,200
cells/mL prior to the availability of HAART.
Results
OVID Medline search yielded 154 results, EMBASE yielded
181 results and the Cochrane Databases yielded 76 results. Four
studies contained data which addressed our study question
(Figure 1). Table 1 includes data on clinical characteristics and
Table 2 includes methodological characteristics of the studies.
Table 3 provides incidence rates of PCP.
Studies differed with respect to study design, populations
studied, sample size, follow-up duration and methods of data
analysis. The first study was a case series in which Soriano et al. [4]
retrospectively reviewed outcomes at 18 months in 53 patients
from Spain in whom secondary prophylaxis for various opportu-
nistic infections was discontinued. Twenty-nine of these patients
had been receiving secondary prophylaxis for PCP. Prophylaxis
was discontinued if both the CD4 count was .100 cells/mL and
VL was ,500 copies/mL after three months of HAART. Mean
(range) baseline CD4 count prior to initiating antiretroviral
therapy was 114 (3–188) cells/mL and VL was 28,456 (1834–
345,879) copies/mL. The CD4 counts at which patients
discontinued secondary prophylaxis were not reported. At the
time of the study, conventional VL load assays could only measure
HIV-RNA as low as 500 copies/mL. Of the 53 patients, only one
person developed PCP. However, the patient had interrupted her
antiretrovirals for 6 weeks due to gastrointestinal upset, and
consequently had a VL.500, 000 copies/mL and CD4 of 46
cells/mL [4]. Thus, if this patient were excluded, the incidence of
PCP would be zero cases over 42 person-years follow-up (PYFU).
The second study was a prospective cohort study of 19 patients
in which D’Egidio et al. [12] followed patients from Ottawa,
Canada with CD4 counts having plateaued at ,200 cells/mL and
undetectable VL while off PCP prophylaxis. During this study in
2007, VL assays which detect virus down to 50 copies/mL, were in
use. There were no episodes of PCP during 261 patient-months of
follow-up [12]. The authors compared the incidence of PCP to the
incidence in 1665 patients at the Multicenter AIDS Cohort Study
(MACS) [13] who were not on HAART and not receiving any
prophylaxis against PCP with CD4 counts ,200 cells/mL. As
approximately 20 cases of PCP per 100 patient-months of
HAART would have been expected, d’Egidio et al. determined
that the risk of developing PCP while on HAART with a CD4
count ,200 cells/mL was significantly different from the risk in
untreated HIV (rate difference 9.2%; 95% CI 5.7, 12.8%, p,0.05)
[12,13].
The third study was performed by The Opportunistic Infections
Project Team of the Collaboration of Observational HIV
Epidemiological Research in Europe (COHERE), a collaboration
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and outcome in HIV-infected individuals from across Europe.
These cohorts include approximately 240,000 adults, 6,400
children and 28,000 mother-infant pairs. The COHERE study
[14] was a prospective study of 12 cohorts in Europe which
analyzed the incidence and risk factors for primary PCP. The
incidences of primary PCP were calculated after stratification by
current use of PCP prophylaxis (‘‘on’’ or ‘‘off’’) and VL. Another
analysis was performed whereby the incidence of primary PCP
after discontinuing prophylaxis in patients having initiated
HAART was performed. This latter analysis was relevant to our
systematic review. In this latter analysis, patients who had never
initiated primary PCP prophylaxis or discontinued prior to starting
HAART were excluded. In the COHERE study patients were also
stratified according to CD4 count, and thus is the only study
providing data about the incidence of PCP in persons with CD4
counts #100 cells/mL and suppressed VL discontinuing prophy-
laxis. Two data sets were of interest to us (CD4 #100 and VL
,400, and CD4 101–200 and VL ,400, who discontinued
prophylaxis). For individuals with CD4 counts between 101–200
cells/mL and VL ,400 copies/mL, there were no episodes of PCP
over 570.4 PYFU, thus yielding an event rate of 0 events per 100
PYFU (95% CI, 0.0, 0.65) [14]. In patients with CD4 counts #100
cells/mL and VL ,400 copies/mL, there were 4 episodes of PCP
over 104.2 person-years follow-up PYFU, for an event rate of 3.84
events per 100 PYFU (95% CI, 1.05, 9.83) [14].
In the fourth and last study, which originated from Taiwan,
Cheng et al. [15] examined the incidence of PCP in three groups
of subjects who discontinued primary and secondary prophylaxis
and those who had never initiated prophylaxis for PCP according
to guidelines. The subpopulation of interest for our review was the
215 patients who achieved undetectable VL and had early
discontinuation of primary (n=130) or secondary (n=85)
prophylaxis for PCP. A single patient who had been receiving
secondary prophylaxis developed PCP after a total period of
observation of 323 PY, giving an incidence rate of 0.31 episodes/
100 PY (95% CI, 0.01, 1.72). This was similar to the incidence in
patients who continued prophylaxis until their CD4 count was
.200 cells/mL (incidence rate 0.45 cases/100 PY (95% CI 0.05,
1.63) and adjusted risk ratio 0.63; 95% CI 0.03, 14.89) [15].
Figure 2 demonstrates the incidence rates (IR) for PCP in
patients with CD4 counts ,200 cells/mL and suppressed VL who
discontinued prophylaxis. The overall incidence of PCP when
these studies are combined is 0.48 events/100 PY (95% CI 0.06,
Figure 1. Flow diagram of literature search for systematic review.
doi:10.1371/journal.pone.0028570.g001
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CD4 count #100 cells/mL and 101–200 cells mL, we were unable
to stratify the overall incidences of PCP based on CD4 count.
Furthermore, only the COHERE study examined incidence of
PCP in the context of discontinuation of primary prophylaxis.
Although the other three studies examined patients discontinuing
both primary and secondary prophylaxis, only Cheng et al.
reported data separately for the discontinuation of primary and
secondary prophylaxis. Hence, we were unable to report incidence
rates of PCP for discontinuation of primary versus secondary
prophylaxis in this systematic review. Furthermore, as the
COHERE study did not indicate the number of individuals with
CD4 counts ,200cells/mL and suppressed VL on HAART who
were adults, it was not possible for us to include rates from the
COHERE study in our systematic review which necessarily
applied to adults only.
Figure 3 depicts this incidence compared to the incidence of
PCP in untreated HIV infection (5.30 events/100 PY, 95% CI 4.1,
6.8). This incidence rate is the pooled rate based on the incidence
of PCP at different CD4 strata in two cohorts reported by
Yazdanpanah et al. (3.1 cases/100 PY, 95% CI 2.0, 4.6 for
individuals with CD4 count 101–200 cells/mL, 6.7 cases/100 PY
(95% CI 3.7, 11.7) for individuals with CD4 51–100 cells/mL and
11.4 cases/100 PY for individuals with CD4 count 0–50 cells/mL
(95% CI 7.5, 17.3) [13]. Figure 3 also depicts the incidence of PCP
in patients with CD4 counts .200 cells/mL with discontinuation
of prophylaxis (0.14 events/100 PY, 95% CI 0, 0.36) [14–16]. The
result was based on data from the COHERE and Cheng studies,
as well as a meta-analysis by Trikalinos et al. [16]. The meta-
analysis by Trikalinos et al. included 14 studies from 1998 until
2001 inclusive [2,3,17–28]. Results from the COHERE, Cheng
et al. and Trikalinos et al. studies were included as they capture the
majority of studies examining the incidence of PCP in patients
with CD4 counts .200 cells/uL who discontinue prophylaxis.
Data that were published after the meta-analysis by Trikalinos et
al. include studies by Abgrall et al [29], Mussini et al [30] and
Zellweger et al [31]. However, incorporation of data from these
later studies did not have an impact on the reported rate of PCP
(range 0.00–1.2 per 100 person-years).
The incidence of PCP in patients with CD4 counts ,200 cells/
mL, before the availability of highly active antiretroviral therapy
and who were receiving PCP prophylaxis, is also demonstrated in
Figure 3 (4.85events/100 PY, 95% CI 0.92–8.78) [32–35]. The
values used to calculate the latter event rate were extracted from
the studies cited in the current guidelines for the prevention of OIs
in HIV-infected adults and adolescents [1], recognizing that there
are additional published reports on this topic. The rates of PCP in
the aforementioned categories are well-established and have been
used frequently in the development of various treatment
guidelines.
Discussion
Recommendations for chemoprophylaxis discontinuation are
based on CD4 counts [1]. However, there are limitations with
using the peripheral blood CD4 count as the sole marker of
immune response. It is estimated that only 2% of the total pool of
CD4 T cells are present in blood at any time, and that even a small
shift in the distribution of cells between the lymphoid tissues and
blood cells may result in a large alteration in peripheral blood
CD4 count [36]. In many studies suggesting it is safe to
discontinue PCP prophylaxis when CD4 count is .200 cells/
mL, this rise in CD4 count was accompanied by a decline in VL
[7]. Furthermore, patients with similar CD4 counts frequently
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These findings suggest that CD4 count alone is not the sole
predictor of susceptibility to PCP.
Improvement in immune function associated with lower VL has
been observed when assessing responses to vaccinations. For
example, lower VLs have been associated with improved responses
to hepatitis A, hepatitis B and varicella vaccinations independent
of CD4 count [37–39]. In a large survey of an HIV-infected
cohort in the United States, a protective effect of PPV-23
vaccination was also shown against all-cause pneumonia, and this
benefit was lost in patients with VL .100,000 copies/mL,
irrespective of the CD4 count [40]. Moreover, in a randomized,
double-blind comparative trial of subunit and virosomal influenza
vaccines for immunocompromised patients, suppression of VL
with HAART was a more important predictor of response to
influenza vaccination than the CD4 count [41].
In addition to discontinuation of prophylaxis after initiation of
HAART, the COHERE study also analyzed the general incidence
of PCP in persons who either never initiated prophylaxis or
discontinued prophylaxis prior to initiating HAAART. They
demonstrated an overall event rate of 0.12 events per 100 PYFU
(95% CI 0.02–0.45) when the CD4 count is between 101–200
cells/mL and VL is suppressed in patients not receiving
prophylaxis. This was similar to the event rate of 0.21 episodes
per 100 PYFU (95% CI 0.08–0.43) in persons with CD4 counts
between 101–200 cells/mL and suppressed VL receiving prophy-
laxis. The low overall incidence rate of PCP when CD4 count is
101–200 cells/mL may serve as supporting evidence that
prophylaxis may not be required in patients with suppressed VL
and CD4 count in the 101–200 cells/mL range.
Another important observation from the COHERE study was
that the risk of PCP differed based on the CD4 strata in individuals
who discontinued prophylaxis after initiating HAART. While it
appeared safe to discontinue prophylaxis with CD4 count between
101–200 cells/mL, the upper confidence interval level of the
incidence rate in persons who discontinued prophylaxis with CD4
count #100 cells/mL after initiating HAART was high (9.83
events per 100 PYFU), suggesting an unacceptably high risk of
PCP in this one study.
The studies included in this review differed in several important
aspects. Most notably, not all studies examined the same primary
outcome (i.e. incidence of PCP during follow-up in patients off
prophylaxis with CD4 counts ,200 cells/mL and suppressed VL),
thus we were unable to perform a meta-analysis. Furthermore,
some studies examined discontinuation of PCP primary prophy-
laxis whereas others examined discontinuation of PCP secondary
prophylaxis. Individuals receiving PCP prophylaxis for primary
compared to secondary prophylaxis may differ in that having had
PCP in the past increases one’s risk for the development of
subsequent episodes [1,9]. Moreover, in addition to adults, the
COHERE cohorts also include children and mother-infant pairs.
However, the number of adults, children and mother-infant pairs
who had CD4+ ,200 cells/mL and suppressed VL on HAART is
not reported.
Studies also differed significantly with respect to sample sizes
and follow-up conditions. Sample size ranged from 19 subjects in
Table 3. Incidence Rates of PCP with Discontinuation of PCP prophylaxis with CD4 count #200 cells/mL and Fully Suppressed Viral
Load (VL).
Author Duration of follow-up (Patient Years) N analyzed Events Rate/100 PY (95% Confidence Interval)
Soriano V et al [4] 42 28 0 0 (0, 8.78)
D’Egidio G et al [12] 21.75 19 0 0 (0, 17.0)
COHERE study group [14] 674.6* NR* 4* 0.59 (0.16, 1.52)*
CD4#100 cells/mL 104.2 NR 4 3.84 (1.05, 9.83)
CD4 100–200 cells/mL 570.4 NR 0 0 (0, 0.65)
Cheng CY et al [15] 323 215 1 0.31 (0.01, 1.71)
Pooled 0.48 (0.06, 0.89)
NR=not reported for subpopulation of interest.
*Based on combined data for CD4#100 and 101–200 cells.
doi:10.1371/journal.pone.0028570.t003
Table 2. Methodological Characterization of Studies on Discontinuation of PCP prophylaxis.
Author Recruitment Period Country Study Designs
Single vs Multiple
Centres
Primary
Outcomes
Outcome
Definitions
Soriano V et al [4] March 1997–March
1998
Spain Case series Single Opportunistic
Infections
NR
D’Egidio G et al [12] NR Canada Prospective cohort Single PCP CDC
COHERE study group
[14]
1997 until NR 29 European
Countries
Prospective cohort (12
cohorts)
Multiple PCP CDC
Cheng CY
et al [15]
April 1997–September
2007
Taiwan Prospective observational Single PCP CDC
NR=nor reported for subpopulation of interest.
CDC=Centre for Disease Control Definition of PCP.
doi:10.1371/journal.pone.0028570.t002
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In the COHERE study, one individual could provide several
episodes of PCP to one CD4/VL stratum, while in the other
studies individual follow-ups are examined. In the Soriano et al.
study, follow-up included time with CD4 count .200 cells/mL,
therefore likely underestimating the incidence of PCP and
overestimating safety by prolonging follow-up. In the Cheng et
al. study, follow-up time included persons with detectable VLs,
thus likely overestimating the incidence. Follow-up durations
whereby patients were off prophylaxis with CD4 counts ,200
cells/mL and suppressed viremia differed among studies. Finally,
studies were performed at different time points and current VL
assays have increased sensitivity compared to those used decades
ago. Whereby older assays could only measure VL to 400–500
copies/mL, newer assays can measure VL down to 40–50 copies/
mL. This may be important due to deleterious effects associated
with even low level plasma viremia, such as direct viral
cytopathogenecity, persistent immune activation with apoptosis
of uninfected cells, and decreased thymic output of naı ¨ve CD4 T
cells [37].
Limiting the use of prophylaxis against PCP to situations where
it has been shown to be most beneficial will minimize adverse drug
reactions. The AIDS Clinical Trials Group (ACTG) 081 was a
randomized clinical trial (RCT) of 842 HIV-infected individuals
which compared the effectiveness of three alternative prophylactic
regimens. There was no difference among treatment arms with
regards to adverse events. Prevalence of patient self-reported
fatigue was 67%, headache 61%, sleep disturbance 50% and
Figure 3. Incidence of PCP in HIV-infected Individuals in Various Situations.
doi:10.1371/journal.pone.0028570.g003
Figure 2. Incidence of PCP in HIV-infected Individuals on Antiretroviral Therapy who Discontinue Prophylaxis with CD4+ Count
,200 cells/mL with Suppressed Viral Load.
doi:10.1371/journal.pone.0028570.g002
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paresthesias, diarrhea and cough all had self-reported prevalences
greater than 30%, demonstrating a substantial burden of adverse
effects [42]. In an earlier meta-analysis by Ioannidis et al., which
examined RCTs comparing efficacy and toxicity of different PCP
prophylaxis regimens, trimethoprim-sulfamethoxazole was almost
universally efficacious at preventing PCP when tolerated. The risk
of discontinuing trimethoprim-sulfamethoxazole due to adverse
reactions depended on dosing schedule and decreased by 43% if
one double-strength tablet was given three times weekly instead of
daily. For dapsone, among 100 patients given 100 mg orally once
daily instead of twice weekly over a year, the authors determined
that 7 fewer patients would develop PCP but 17 more would have
significant toxic reactions [43]. Of the 4 studies included in our
systematic review, only Cheng et al. reported the incidence
adverse effects due to PCP prophylaxis. They estimated the crude
incidence of adverse effects for primary prophylaxis with
trimethoprim-sulfamethoxazole to be 23.3%, of which 13.3%
were due to skin rashes, 6.8% due to leukopenia, 2.9% due to
gastrointestinal intolerance and 0.4% due to Stevens-Johnson
syndrome. Of 47 patients (21.8%) who developed adverse events
leading to discontinuation of secondary prophylaxis, adverse
events included skin rashes in 17.6%, gastrointestinal intolerance
in 2.3% and leukopenia in 1.9% [15]. However, it should be noted
that these rates do not apply exclusively to individuals with CD4
counts ,200 cells/mL with suppressed VL on HAART.
An important limitation of our systematic review is the
heterogeneity between the studies examined. Although this
precluded us from performing a meta-analysis, we pooled results
to include the totality of available, relevant evidence in our
systematic review. Another limitation of our study is its
retrospective nature in which we were dependent upon the
availability and accuracy of data reported by others. Furthermore,
none of the studies included were randomized controlled trials,
eliminating the ability to control for confounding factors which
may have influenced results.
The question of whether it is safe to discontinue prophylaxis
with suppressed VL and CD4 count ,200 cells/mL would be best
addressed with an RCT. However, this is unlike unlikely to occur
in the foreseeable future. As a meta-analysis was not possible due
to the heterogeneity between studies, here we conducted a
systematic review of the available evidence. Though studies are
few in number, when examined together there is sufficient
evidence to demonstrate that the risk of PCP infection in HIV-
infected individuals on HAART with suppressed VL is sufficiently
low to allow discontinuation of primary prophylaxis, despite a
CD4 count between 101–200 cells/mL. Given the low overall risk
of PCP with CD4 count between 101–200 cells/mL, combined
with the drawbacks of prophylaxis for OIs, we suggest a revision of
clinical guidelines for primary prophylaxis is merited to include
consideration of the VL. However, as only one study examined the
risk of PCP prophylaxis discontinuation at different CD4 strata,
including #100 cells/mL, it may not be appropriate to apply this
recommendation to individuals with CD4 counts of #100 cells/mL
at this time.
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